A randomized phase II trial of cisplatinum plus mitomycin-C plus vinorelbine and carboplatin plus vinorelbine in advanced non-small cell lung cancer

  • Authors:
    • M Colleoni
    • G Vicario
    • F Pancheri
    • G Sgarbossa
    • P Nelli
    • P Manente
  • View Affiliations

  • Published online on: March 1, 1997     https://doi.org/10.3892/ijo.10.3.619
  • Pages: 619-622
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Vinorelbine represents one of the most active agents in advanced non-small cell lung cancer (NSCLC), with response rates of 14-33%. We therefore evaluated the activity and tolerability of two novel vinorelbine-containing regimens in stage IIIB-IV NSCLC. Fifty-two patients were enrolled in a randomized phase II study of cisplatinum (100 mg/m(2)) day 1, mitomycin-C (8 mg/m(2)) day 1, and vinorelbine (25 mg/m(2)) days 1 and 8 (Arm A); and carboplatin (400 mg/m(2)) day 1, in combination with vinorelbine (25 mg/m(2)) days 1 and 8 (Arm B). Cycles were repeated every 3 weeks. All patients were assessable for reponse and side effects. Patients were well balanced between the two Arms in terms of major characteristics. A total of 98 and 91 cycles were delivered respectively in Arm A and Arm B. Eleven objective responses (42%; 95% confidence interval 26-63%) were observed in Arm A and 7 responses (27%; 95% confidence interval 12-48%) in Arm B. Main toxicity was mild or moderate, nausea and vomiting for Arm A and hematological for Arm B. Other side effects included infections and phlebitis and were similar for the two Arms. In conclusion, both schedules demonstrated activity in advanced NSCLC. The three-drug regimen appeared very promising in terms of activity and manageable toxicity.

Related Articles

Journal Cover

March 1997
Volume 10 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Colleoni, M., Vicario, G., Pancheri, F., Sgarbossa, G., Nelli, P., & Manente, P. (1997). A randomized phase II trial of cisplatinum plus mitomycin-C plus vinorelbine and carboplatin plus vinorelbine in advanced non-small cell lung cancer. International Journal of Oncology, 10, 619-622. https://doi.org/10.3892/ijo.10.3.619
MLA
Colleoni, M., Vicario, G., Pancheri, F., Sgarbossa, G., Nelli, P., Manente, P."A randomized phase II trial of cisplatinum plus mitomycin-C plus vinorelbine and carboplatin plus vinorelbine in advanced non-small cell lung cancer". International Journal of Oncology 10.3 (1997): 619-622.
Chicago
Colleoni, M., Vicario, G., Pancheri, F., Sgarbossa, G., Nelli, P., Manente, P."A randomized phase II trial of cisplatinum plus mitomycin-C plus vinorelbine and carboplatin plus vinorelbine in advanced non-small cell lung cancer". International Journal of Oncology 10, no. 3 (1997): 619-622. https://doi.org/10.3892/ijo.10.3.619